These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
339 related articles for article (PubMed ID: 25543193)
41. Phosphate binders in moderate chronic kidney disease: where do we stand? Bellasi A; Cozzolino M; Adragao T; Di Iorio B; Russo D J Nephrol; 2013; 26(6):993-1000. PubMed ID: 23543481 [TBL] [Abstract][Full Text] [Related]
42. Diagnosis and management of mineral and bone disorders in infants with CKD: clinical practice points from the ESPN CKD-MBD and Dialysis working groups and the Pediatric Renal Nutrition Taskforce. Bacchetta J; Schmitt CP; Bakkaloglu SA; Cleghorn S; Leifheit-Nestler M; Prytula A; Ranchin B; Schön A; Stabouli S; Van de Walle J; Vidal E; Haffner D; Shroff R Pediatr Nephrol; 2023 Sep; 38(9):3163-3181. PubMed ID: 36786859 [TBL] [Abstract][Full Text] [Related]
43. [Mineral and bone disorder in chronic kidney disease : Critical appraisal of pharmacotherapy]. Brunkhorst R Internist (Berl); 2014 Mar; 55(3):334-9. PubMed ID: 24522558 [TBL] [Abstract][Full Text] [Related]
44. Hyperphosphatemia and Chronic Kidney Disease: A Major Daily Concern Both in Adults and in Children. Bacchetta J; Bernardor J; Garnier C; Naud C; Ranchin B Calcif Tissue Int; 2021 Jan; 108(1):116-127. PubMed ID: 31996964 [TBL] [Abstract][Full Text] [Related]
45. Chronic Kidney Disease-Mineral Bone Disorder in the Elderly Peritoneal Dialysis Patient. Heaf JG Perit Dial Int; 2015 Nov; 35(6):640-4. PubMed ID: 26702005 [TBL] [Abstract][Full Text] [Related]
46. Adynamic bone disease: from bone to vessels in chronic kidney disease. Bover J; Ureña P; Brandenburg V; Goldsmith D; Ruiz C; DaSilva I; Bosch RJ Semin Nephrol; 2014 Nov; 34(6):626-40. PubMed ID: 25498381 [TBL] [Abstract][Full Text] [Related]
47. The challenge of controlling phosphorus in chronic kidney disease. Cannata-Andía JB; Martin KJ Nephrol Dial Transplant; 2016 Apr; 31(4):541-7. PubMed ID: 25770169 [TBL] [Abstract][Full Text] [Related]
48. The complexity of chronic kidney disease-mineral and bone disorder across stages of chronic kidney disease. Graciolli FG; Neves KR; Barreto F; Barreto DV; Dos Reis LM; Canziani ME; Sabbagh Y; Carvalho AB; Jorgetti V; Elias RM; Schiavi S; Moysés RMA Kidney Int; 2017 Jun; 91(6):1436-1446. PubMed ID: 28318623 [TBL] [Abstract][Full Text] [Related]
49. Role of nutritional vitamin D in chronic kidney disease-mineral and bone disorder: A narrative review. Shen Y Medicine (Baltimore); 2023 Apr; 102(14):e33477. PubMed ID: 37026958 [TBL] [Abstract][Full Text] [Related]
50. [Management of bone and mineral metabolism disorders before the dialysis stage remains still perfectible. Data from the French Phosphorus and Calcium Survey Photo-Graphe]. Jean G; Daugas É; Roth H; Drueke T; Bouchet JL; Hannedouche T; London G; Fouque D Nephrol Ther; 2017 Nov; 13(6):470-478. PubMed ID: 28843391 [TBL] [Abstract][Full Text] [Related]
51. Calcium regulation and bone mineral metabolism in elderly patients with chronic kidney disease. Tejwani V; Qian Q Nutrients; 2013 May; 5(6):1913-36. PubMed ID: 23760058 [TBL] [Abstract][Full Text] [Related]
52. The effects of non-calcium-based phosphate binders versus calcium-based phosphate binders on cardiovascular calcification and bone remodeling among dialysis patients: a meta-analysis of randomized trials. Liu L; Wang Y; Chen H; Zhu X; Zhou L; Yang Y Ren Fail; 2014 Sep; 36(8):1244-52. PubMed ID: 25019348 [TBL] [Abstract][Full Text] [Related]
53. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis. Brandi L Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159 [TBL] [Abstract][Full Text] [Related]
54. The future of phosphate binders: a perspective on novel therapeutics. Cernaro V; Santoro D; Lucisano S; Nicocia G; Lacquaniti A; Buemi M Expert Opin Investig Drugs; 2014 Nov; 23(11):1459-63. PubMed ID: 25243756 [TBL] [Abstract][Full Text] [Related]
55. [Kidney and bone update : the 5-year history and future of CKD-MBD. Bone metabolic marker in hemodialysis patients update]. Okuno S Clin Calcium; 2012 Jul; 22(7):1009-17. PubMed ID: 22750933 [TBL] [Abstract][Full Text] [Related]
56. Coronary risk score for mineral bone disease in chronic non-diabetic hemodialysis patients: results from a prospective pilot study. David C; Bover J; Voiculet C; Peride I; Petcu LC; Niculae A; Covic A; Checherita IA Int Urol Nephrol; 2017 Apr; 49(4):689-700. PubMed ID: 27990611 [TBL] [Abstract][Full Text] [Related]
57. [Bone and calcium update; diagnosis and therapy of metabolic bone disease update. Advances in treatment of CKD-MBD]. Mizobuchi M; Nakazawa A; Akizawa T Clin Calcium; 2011 Dec; 21(12):159-66. PubMed ID: 22133835 [TBL] [Abstract][Full Text] [Related]
58. Chronic Kidney Disease Circulating Calciprotein Particles and Extracellular Vesicles Promote Vascular Calcification: A Role for GRP (Gla-Rich Protein). Viegas CSB; Santos L; Macedo AL; Matos AA; Silva AP; Neves PL; Staes A; Gevaert K; Morais R; Vermeer C; Schurgers L; Simes DC Arterioscler Thromb Vasc Biol; 2018 Mar; 38(3):575-587. PubMed ID: 29301790 [TBL] [Abstract][Full Text] [Related]
59. Laboratory abnormalities in CKD-MBD: markers, predictors, or mediators of disease? Evenepoel P; Rodriguez M; Ketteler M Semin Nephrol; 2014 Mar; 34(2):151-63. PubMed ID: 24780470 [TBL] [Abstract][Full Text] [Related]
60. Phosphate handling in CKD-MBD from stage 3 to dialysis and the three strengths of lanthanum carbonate. Cozzolino M; Bruschetta E; Cusi D; Montanari E; Giovenzana ME; Galassi A Expert Opin Pharmacother; 2012 Nov; 13(16):2337-53. PubMed ID: 23033914 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]